D&D Pharmatech Past Earnings Performance
Past criteria checks 0/6
D&D Pharmatech has been growing earnings at an average annual rate of 6.6%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 15.4% per year.
Key information
6.6%
Earnings growth rate
11.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 15.4% |
| Return on equity | -13.2% |
| Net Margin | -79.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How D&D Pharmatech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 13,242 | -10,548 | 7,211 | 16,790 |
| 31 Mar 24 | 15,960 | -3,307 | 7,819 | 18,381 |
| 31 Dec 23 | 18,677 | 3,934 | 8,427 | 19,973 |
| 30 Sep 23 | 17,002 | -90,520 | 8,461 | 25,672 |
| 31 Dec 22 | 611 | -136,067 | 9,287 | 47,125 |
| 31 Dec 21 | 1,364 | -68,224 | 8,823 | 56,826 |
| 31 Dec 20 | 0 | -63,406 | 7,353 | 50,805 |
| 31 Dec 19 | 0 | -6,359 | 4,010 | 19,550 |
| 31 Dec 18 | 348 | -20,002 | 1,336 | 188 |
Quality Earnings: A347850 is currently unprofitable.
Growing Profit Margin: A347850 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A347850 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare A347850's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A347850 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A347850 has a negative Return on Equity (-13.15%), as it is currently unprofitable.